PDGFR ALPHA REARRANGEMENT T(4Q12), HEPARIN BLOOD

image not found

NABL Cap Accredited    
This test detects rearrangements involving the PDGFRA gene located at chromosome 4q12, which are associated with certain myeloid and lymphoid neoplasms, particularly those with eosinophilia. Identifying this abnormality helps confirm diagnosis, guide targeted therapy, and determine prognosis. The presence of PDGFRA rearrangements makes patients potentially responsive to tyrosine kinase inhibitors such as imatinib. Metropolis Healthcare performs this test using advanced molecular techniques for accurate and sensitive detection

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 5,405.00

Sample Type: Sodium Heparin Blood

Fasting Not Required


Notes: T0016

Frequently Asked Questions (FAQ's):

What does this test check for?
It detects genetic rearrangements of the PDGFRA gene, most commonly associated with eosinophilia-related blood cancers.

Why is this test important?
It helps confirm the diagnosis of specific myeloid or lymphoid neoplasms and guides targeted treatment decisions.

What sample is required?
A heparin blood sample is used for the analysis.

Is any preparation needed?
No fasting or special preparation is required.

How is the test performed?
Molecular techniques such as FISH or RT-PCR are used to identify PDGFRA rearrangements.

Who should undergo this test?
Patients with unexplained eosinophilia or suspected myeloid/lymphoid neoplasms.

Can this test impact treatment options?
Yes, PDGFRA-positive cases often respond well to targeted therapy like imatinib

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab